drugset / Trial / NCT05884801
Phase I Study of QLS1103 in Subjects With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
This study is a phase I, dose escalation and dose expansion study of QLS1103, to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of QLS1103 in subjects with advanced solid tumors.
Timeline
- Start
- 2023-06-30
- Primary completion
- 2025-01-30
- Completion
- 2025-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QLS1103 | Unknown | — | Oral |